Dermata (DRMA) CFO Kyri K. Van Hoose Buys 102,040 Shares

What Happened
Kyri K. Van Hoose, SVP and Chief Financial Officer of Dermata Therapeutics (DRMA), acquired 102,040 shares of common stock in a private placement on August 16, 2026. The purchase price for each share (together with accompanying warrants) was $1.47, for a total cash outlay of approximately $149,998.80 (~$150K). The Form 4 also reports the acquisition of two derivative instruments (series E and series F warrants) tied to the same 102,040 shares, which were issued together with the common shares in the private placement.

Key Details

• Transaction date: August 16, 2026; Form 4 filed August 18, 2026 (timely filing).
• Price paid: $1.47 per share (purchase price covers each share plus accompanying warrants).
• Total cash consideration (common shares): 102,040 × $1.47 = $149,998.80 (~$150K).
• Derivatives: Two warrants were issued with the shares (series E and series F). Both become exercisable only after stockholder approval to issue the underlying shares; series E expires five years after such approval, series F expires two years after such approval.
• Exercise limitation: Neither warrant may be exercised to the extent doing so would cause the holder (and affiliates) to beneficially own more than 9.99% of outstanding common stock (subject to certain exceptions).
• Exemption: The shares and accompanying warrants were purchased together in a private placement exempt from Section 16(b) under Rule 16b‑3(d)(1).
• Shares owned after the transaction: Not specified in the excerpt provided.

Context
This filing reports a direct purchase (a buy), often viewed as a stronger signal of insider confidence than routine sales, though it reflects a private placement rather than open-market buying. The warrants are not immediately exercisable—they require stockholder approval before conversion into additional shares and are subject to expiration windows and a 9.99% ownership cap.